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Human immunodeficiency virus type 1 (HIV-1) infection is initiated by the binding of the viral envelope protein gp120 to the host cell CD4
receptor through a high-affinity interaction involving amino acids 39–60 within the CD4. We obtained evidence demonstrating functional
importance of this region in CD4 for viral infectivity by showing that a synthetic peptide corresponding to this CD4 sequence exhibited
competitive binding to gp120 and significantly reduced infection by diverse HIV-1 strains, including primary isolates. Treatment of HIV-1-
infected cells with this CD4 peptide induced shedding of gp120 and exposure of the transmembrane protein gp41. Furthermore, we observed that
deletion or substitution of arginine at position 59 (Arg59) within the CD4 peptide sequence abrogated its gp120-shedding property. These results
indicate a critical role for Arg59 in the CD4 for conformational changes in gp120 during the sequential process of entry and infection by HIV-1.
© 2007 Published by Elsevier Inc.Keywords: HIV-1; CD4 peptides; Arg59; Infection inhibition; gp120 sheddingIntroduction
The human immunodeficiency virus (HIV-1) infection
process begins with the binding of the viral surface envelope
protein gp120 to the cellular CD4 receptor (Lasky et al., 1987;
Olshevsky et al., 1990). The gp120 binds to cellular CD4
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doi:10.1016/j.virol.2006.12.00360 within the second complementarity-determining region
(CDR2) of CD4 (Arthos et al., 1989; Brodsky et al., 1990).
Based on crystal structure analyses, phenylalanine at position
43 (Phe43) and arginine at position 59 (Arg59) within the high-
affinity gp120-binding region of CD4 are predicted to make
multiple contacts centered on Asp368, Glu370, and Trp427 of the
C3 and C4 regions of gp120 (Kwong et al., 1998, 2000).
Specifically, it has been shown that Asp368 of gp120 forms a salt
bridge with Arg59 of the CD4 receptor (Brodsky et al., 1990;
Peterson and Seed, 1988; Wyatt and Sodroski, 1998), and that
the viral gp120 and cellular CD4 molecule form hydrogen
bonds, which bridge the two proteins (Wyatt and Sodroski,
1998). These interactions are believed to trigger conformational
changes in the viral gp120 (Sattentau and Moore, 1991) that
facilitate binding of the gp120/CD4 complex to the cellular co-
receptor (Deng et al., 1996; Salzwedel et al., 2000; Trkola et al.,
1996; Wu et al., 1996). The co-receptor interaction exposes the
viral transmembrane protein gp41, which allows fusion between
the virus and cell membrane (Furuta et al., 1998; Munoz-
Barroso et al., 1998).
Table 1
Amino acid sequences of the various peptides
Peptide Amino acid sequence
CD4 peptides
N22S 39NQGSF43LTKGPSKLNDRADSRR59S60
N22S–F43A 39NQGSA43LTKGPSKLNDRADSRR59S60
N22S-R59A 39NQGSF43LTKGPSKLNDRADSRA59S60
N22S–F43A-R59A 39NQGSA43LTKGPSKLNDRADSRA59S60
N18D 39NQGSF43LTKGPSKLNDRAD
S4S SRR59S60
S4Rd SRS59R60 (scrambled amino acid sequence of S4S)
Irrelevant control peptide
I15R IFPGKRTIVAGQRGR
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CD4 for HIV-1 infection was also established in studies
employing CD4-mimetics, peptides encompassing the amino
acids in CD4 predicted to be involved in gp120 interaction, and
the full-length soluble form of the CD4 (sCD4). Martin et al.
(2003) described engineering of a CD4 miniprotein using a
scyllatoxin scaffold that consisted of CD4 amino acids involved
in interactions critical for gp120 binding, and showed strong
inhibition of infection by various laboratory adapted and
primary X4 and R5 isolates of HIV-1. The proposed mechanism
of action included Phe43 in the miniprotein to block the
engagement of the CD4-Phe43 cavity by gp120, and Arg9 in the
miniprotein which, in the same manner as CD4-Arg59, to form
double H-bonds with Asp368 in gp120. Lifson et al. (1988)
employed benzylated CD4 peptides corresponding to amino
acids 76–94 that competed with CD4 for binding to gp120 and
effectively prevented HIV-1 infection. The soluble form of CD4
(sCD4) was shown in vitro to effectively bind to gp120 on the
virion or on HIV-infected cells causing dissociation of the
gp120 and concurrently exposing the gp41 (Berger et al., 1992;
Hart et al., 1991).
Based on the literature reports describing the CDR2 region in
CD4, encompassing amino acids 39–60, as important for the
high-affinity gp120-binding, we hypothesized that synthetic
peptides corresponding to this CD4 region should be effective
in competitively binding to the viral envelope protein causing
gp120 dissociation. In this investigation, we obtained evidence
to show that a synthetic peptide N22S, encompassing the 22
amino acids in the high-affinity gp120-binding region in CD4,
exhibited specific binding to gp120 and significantly reduced
infectivity of diverse HIV-1 isolates by inducing premature
conformational changes in gp120 including exposure of gp41
and gp120-shedding. Deletion or substitution of the Arg59
within this peptide sequence abrogated the gp120-shedding
activity suggesting that Arg59 in the CD4 is important for
inducing the conformational changes in the viral envelope
during the multi-step process of HIV-1 infection.
Results
Functional significance of the high-affinity gp120-binding
region of CD4 for infection by diverse HIV-1 strains
To determine the functional significance of the high-affinity
gp120-binding region ofCD4, specifically forHIV-1 infection,we
synthesized a peptide, N22S, corresponding to this entire 22
amino acid region of CD4 (Table 1) and tested its effect on the
infectivity of various strains of HIV-1 using two separate assays.
In the first one, we employed the fluorescence-based GHOST
assay and the cell lines encoding the HIV-1 LTR-driven GFP
expression for determining the infectivity of the different HIV-1
strains pretreatedwith theCD4 peptide (Morner et al., 1999;Weiss
and White, 1993). As shown in Fig. 1, pretreatment of HIV-1IIIB
(X4 virus) with the CD4 peptide N22S resulted in an 84%
decrease in infection, compared to that with the medium-treated
virus, in the GHOST-X4 cells, that express the CXCR4
chemokine co-receptor for HIV-1 (infected cells decreased from47% to 8%). Similarly, pretreatment of HIV-1YU2 (R5 virus) with
the N22S peptide decreased the infectivity by 92%, compared to
medium control, in GHOST-Hi-5 cells, which express the CCR5
chemokine co-receptor (reduction in the infected cells from 38%
to 3%). The relative levels of decrease in the infectivity of HIV-
1IIIB andHIV-1YU2 by the N22S peptidewere comparable to those
observed with soluble CD4 (sCD4) treatment (90% and 91%, for
the two different virus strains, respectively), but the unrelated
control peptide, I15R did not show any effect (≤14.5%
inhibition). On the other hand, the N22S peptide showed no
effect on the infection by HIV-1NDK, an X4 strain of HIV-1 that
exhibits CD4-independent infection of cells (Dumonceaux et al.,
1998), indicating the specificity of the CD4 peptide to target HIV-
1 envelope, and in particular the gp120–CD4 interaction (Fig. 1).
As expected, the reverse transcriptase inhibitor AZT showed a
strong inhibition of infection by all the virus strains tested.
Next we tested the effect of the N22S peptide on the infectivity
of HIV-1IIIB or HIV-1YU2 in human peripheral blood mononuclear
cells (PBMC) by determining changes in the levels of reverse
transcriptase (RT) activity in the culture supernatants (Pericle et al.,
1998). The virus inoculum was pretreated with sCD4, the N22S
peptide, the irrelevant control peptide I15R, or medium before
using for the infection of the PHA-stimulated PBMC. Ten days
after infection, the culture supernatants were harvested and
assayed for RT activity as a measure of productive virus infection.
Significant reduction in RT activity indicating loss of infectivity
was observed with the N22S treatment for both the X4 and R5
viruses (Fig. 2A). For the infection of HIV-1IIIB, relative to the
medium treatment, the N22S treatment resulted in 80% reduction
in the infectivity compared to 81.5%with sCD4. Similarly, in cells
infected with HIV-1YU2, we observed 75% and 77% reduction in
the RT activity when the virus was pretreated with sCD4 and
N22S, respectively. The control I15R peptide showed no
inhibitory effect against either of the two viruses used in these
experiments.
Arg59-containing peptides corresponding to the high-affinity
gp120-binding region of CD4 inhibit infection of diverse HIV-1
strains
Literature reports describing the crystal structure and func-
tional analysis of the 22-amino acid high-affinity gp120-binding
Fig. 2. CD4 peptides inhibit infection of human PBMC by laboratory as well as
primary isolates of HIV-1. Antiviral activity of the CD4 peptides was
determined for laboratory-adapted and primary X4 strains (HIV-1IIIB and
93ZR001.3, respectively) and R5 strains (HIV-1YU2 and 93MW96.5.26,
respectively) by analyzing the infected normal donor PBMC culture super-
natants for reverse transcriptase (RT) activity. The RT activities are shown as the
cpm values for 10 μl of the culture supernatant in each case. Numbers on top of
the bars represent the % decrease of infection. (B) The S4S peptide inhibits
infection by primary isolates of HIV-1. Envelope sequences for seven different
primary isolates of HIV-1 (clades A–G) were used to prepare pseudotyped HIV-
1 and either not treated or treated with the S4S peptide or the control S4R
peptide prior to infecting C8166 cells. Results are expressed as the amount of
reverse transcriptase activity (cpm/ml). All peptide treatments were done at
10 μg/ml. The results are an average of three separate experiments and error bars
represent standard deviation.
Fig. 1. Infection of HIV-1IIIB, HIV-1YU2, and HIV-1NDK in the GHOST X4 and
GHOST Hi5 cells, respectively, is inhibited by Arg59-containing CD4 peptides
from the high-affinity gp120-binding site. The inhibition of infection by
different treatments to the virus is shown as reduction in the percentage of GFP-
positive cells compared to cells infected with untreated virus. Infection by the
NDK strain of HIV-1, which infects in a CD4-independent manner, is not
inhibited by sCD4 or the CD4 peptides. All peptide treatments were done at
10 μg/ml. All the three HIV-1 strains were susceptible to inhibition by AZT
(1 μM). The results are an average of three separate experiments and error bars
represent standard deviation.
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gp120-interaction (Kwong et al., 1998). To determine the
importance of this amino acid for the infectivity of different
HIV-1 strains, we employed CD4 peptides corresponding to this
high-affinity gp120-binding region that do or do not contain
Arg59 and compared their anti-HIVactivities to that seen with the
N22S peptide. The N18D peptide corresponding to the amino-
terminal 18 amino acids of the N22S peptide is devoid of Arg59
(Table 1), and pretreatment of the virus inoculumwith this peptide
resulted in only a modest decrease (14.5%) in the infectivity of
both X4 and R5 strains (Fig. 1). On the other hand, a shorter
peptide, S4S, corresponding to the carboxy-terminal four amino
acids of N22S, including Arg59, showed a significant decrease in
the infectivity of X4 and R5 strains, an effect comparable to that
observedwith sCD4 and theN22S peptide (Fig. 1). Similar results
were obtained for the infection of human PBMC byHIV-1IIIB and
HIV-1YU2 strains as seen in terms of reduction in the RT activity
by 15.7% and 18.7% forN18D, and 89.5% and 79.5% for S4S, for
the two strains, respectively (Fig. 2A). Furthermore, as shown in
Fig. 2A, the effects of the N22S and S4S peptides were similar for
infection by the laboratory strains HIV-1IIIB and HIV-1YU2 (78%
and 75%, respectively) as well as HIV-1 pseudotyped with
envelope proteins corresponding to primary X4 and R5 isolates
93MW965.26 and 93ZR001.3 (83.6% and 86%, respectively).
The control peptide S4R, with scrambled amino acid sequence of
the S4S peptide, did not show a significant effect on the infection
of either the laboratory or the primary HIV-1 strains (Figs. 1 and
2A). These results suggest an important role for Arg59 in the high-
affinity gp120-binding region of CD4 for productive infection by
diverse HIV-1 strains. In support of this conclusion, we observed
that infection by seven different HIV-1 strains pseudotyped for
expressing envelope sequences corresponding to primary isolates
representing different clade isolates was also strongly affected by
pretreatment of the virus inoculum with the S4S peptide, in termsof significant reduction in RT activity in the infected culture
supernatants (Fig. 2B).
Reduction in the HIV-1 infectivity by the Arg59-containing CD4
peptides is concentration-dependent and not due to cellular
toxicity
We determined whether the observed reduction in the
infectivity of diverse HIV-1 strains by the CD4 peptides
N22S and S4S is dependent on the peptide concentration by
employing the GHOST assay and representative X4 and R5
strains of HIV-1. The virus inoculum was incubated with either
the N22S or S4S peptide at various concentrations ranging from
0.001 to 10 μM prior to infecting the host cells and observed a
progressive decrease in infection corresponding to increasing
Fig. 3. Inhibition of HIV-1 infection by CD4 peptides is concentration-
dependent and without cellular toxicity. (A) CD4 peptide concentration-
dependent inhibition of HIV-1 infection. GHOST X4 and GHOST hi5 cells were
infected with HIV-1IIIB and HIV-1YU2, respectively after pretreatment with
sCD4 or the CD4 peptides at increasing concentrations. In the cases of both the
viruses tested, the % inhibition increased in a concentration-dependent manner.
No changes in cell viability were observed at any of the concentrations tested for
sCD4 as well as the two CD4 peptides (B). The results are an average of three
separate experiments and error bars represent standard deviation.
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concentration (IC50) for N22S was 0.09 μM against both X4
and R5 strains of HIV-1, while the corresponding values for S4SFig. 4. Arg59-containing peptides from the high-affinity gp120-binding region of CD4
gp120, corresponding to HIV-1IIIB, in the presence of the various CD4 peptides wa
decrease in sCD4 binding. The results are an average of three separate experimentswere 0.035 μM and 0.5 μM, respectively, against the two
viruses. In these experiments, the CD4 peptides tested at any of
the different concentrations showed no adverse effect on the
cells as seen in terms of the viable cell counts that were nearly
identical to those of untreated cells (Fig. 3B).
Arg59-containing peptides from the high-affinity gp120-binding
region of CD4 exhibit specific binding to gp120 and inhibition
of HIV-1 infection
We investigated whether the effect of Arg59-containing CD4
peptides on the infectivity of HIV-1 was associated with their
capacity to specifically bind to the HIV-1 envelope surface
protein gp120, in a manner similar to that known for sCD4 (Fig.
4). We observed that peptides N22S and S4S, both containing
the Arg59, significantly decreased binding of sCD4 to gp120
(86% and 83%, respectively), but the N18D peptide that does
not contain the Arg59 showed a minimal 13% inhibition (Fig. 4).
To further confirm the importance of Arg59, we tested variations
of the N22S peptide that contained alanine substitution for
Arg59 and/or Phe43, another amino acid reported to be critical
for gp120–CD4 interaction (Table 1). The N22S-R59A and the
N22S-F43A-R59A peptides with alanine substitution for Arg59
alone or both Phe43 and Arg59 reduced sCD4 binding to gp120
by 27% and 35%, respectively, while the N22S-F43A peptide in
which the Phe43, but not the Arg59, is changed to alanine
showed 80% reduction (Fig. 4). The unrelated control peptide
I15R and the S4R peptide with scrambled amino acid sequence
to that in S4S peptide showed only a slight decrease in the
binding of sCD4 to gp120 (8.7% and 7% respectively). These
results further support the key role of Arg59 in gp120–CD4
interactions.
Next we sought to determine whether the observed
importance of Arg59 within the high-affinity gp120-bindng
region of CD4 for binding to gp120 is associated with the
infectivity of HIV-1. For this, we compared the different
modified versions of the N22S peptide to the unmodified N22S
peptide for their effect on the infectivity of HIV-1IIIB in two
different cells, the HeLa-β-gal cells and GHOST-X4 cells using
the MAGI and GHOST assays, respectively (Fig. 5). In both
these assays, compared to infection with untreated virus,inhibit binding of sCD4 to recombinant gp120. Binding of sCD4 to recombinant
s determined by typical ELISA analysis. Numbers next to the bars represent %
and error bars represent standard deviation.
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N22S peptide, where Phe43 is substituted with alanine (N22S-
F43A), showed significant inhibition of infection (84% and
67% inhibition with the two peptides respectively). On the other
hand, the N22S-R59A peptide with alanine substitution for
Arg59 alone and the N22S-F43A-R59A peptide where both
Phe43 and Arg59 are substituted with alanine residues, exhibited
lower HIV-inhibitory effects (43.11% and 40.6%, respectively)
that did not reach statistical significance. These results for the
modified N22S peptides, together with those observed for
competitive inhibition of sCD4 binding to gp120, support the
importance of Arg59 during the HIV-1 infection. None of the
N22S peptide variants tested exhibited cellular cytotoxicity
indicating the specificity of their anti-HIV activity (Fig. 5B).
Arg59 within the high-affinity gp120-binding region of CD4 is
important for CD4-mediated conformational changes in gp120
Based on the results showing specific binding to gp120, and
decreased HIV-1 infectivity when used for pretreatment of the
virus inoculum, we hypothesized that the Arg59-containing
CD4 peptides from the high-affinity gp120-binding region may
induce conformational changes in gp120 leading to its shedding
and exposure of the transmembrane protein gp41 on virus-
infected cells. If this is correct, it will be reminiscent of the
activity associated with sCD4 (Berger et al., 1992; Hart et al.,Fig. 5. CD4 peptides with alanine substitutions for Phe43 and/or Arg59 inhibit infecti
determined for HIV-1 infection of GHOST X4 and HeLa-β-gal cells in terms of perce
Both N22S and N22S-F43A showed strong inhibition of infection. The various pep
exhibited cytotoxicity to the cells (B). The results are an average of three separate e1991). To test this hypothesis, we incubated gp120 expressing
H9 cells chronically infected with HIV-1IIIB (H9/HIV-1IIIB) with
sCD4, N22S, S4S, or an unrelated control peptide for 1 h at
37 °C after which, the cells were collected and analyzed for the
amounts of gp120 and gp41 by flow cytometry. As shown in
Fig. 6A, treatment with N22S and S4S showed a decrease in the
amount of gp120 on the cells by 70% and 74%, respectively,
which is similar to that observed with the sCD4-treatment
(75%). Furthermore, concurrent with the decrease of gp120
levels, there was an increase in the amount of gp41 by 3.5-, 3.7-,
and 4.0-fold, respectively with N22S, S4S, and sCD4 (Fig. 6B).
Treatment of the cells with the unrelated control peptide I15R
resulted in no significant changes in the levels of gp120 and
gp41.
Since the modified versions of the N22S peptides where
Phe43 and/or Arg59 were changed to alanine showed
differential levels of inhibition of HIV-1 infectivity, we tested
their effect on inducing gp120 shedding and exposure of the
transmembrane envelope glycoprotein gp41. Treatment of the
chronically infected H9/HIV-1IIIB cells with the N22S-R59A
peptide, where the Arg59 has been modified to alanine, or the
N22S-F43A-R59A peptide, where both Phe43 and Arg59 were
substituted with alanine residues, showed no change in the cell
surface levels of gp120 and gp41 (Figs. 6A and B). However,
treatment with the N22S-F43A peptide, where Phe43 is
changed to alanine but Arg59 was unchanged, resulted in aon of HIV-1IIIB. The inhibitory activity of the various CD4 peptides shown was
ntage of GFP-positive cells and the numbers of β-gal-positive cells, respectively.
tides shown were used at 10 μg/ml at 37 °C for 30 min. None of the peptides
xperiments and error bars represent standard deviation.
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Fig. 7. Arg59-containing CD4 peptides from the high-affinity gp120-binding
region induce gp120 release from cells infected with HIV-1. The H9/HIV-1IIIB
cells were treated as indicated (at 10 μg/ml for each treatment) and the culture
supernatants were concentrated and subjected to western blot analyses to detect
gp120 using mouse anti-gp120 antibody 1121 as the primary antibody and goat
anti-mouse horseradish peroxide as secondary antibody. Protein quantification
confirmed the loading of 30 μg of protein for each sample for the electrophoresis.
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concurrent with an increase in the gp41 levels (3.5-fold). None
of these CD4 peptides was found to interfere with anti-gp120
mAb binding to gp120 (Supplemental Fig. 1). These results
were comparable to those seen after treatment of the cells with
sCD4 and the unmodified N22S peptide.
We then investigated whether the decrease in cell surface
gp120 after the different treatments as shown in Fig. 6, is
associated with gp120-shedding. For this, we concentrated the
supernatants from the H9/HIV-1IIIB cells after the various
treatments, determined the amount of protein present in each
sample, and resolved them on a 10% agarose gel for western
blot analysis with an anti-gp120 antibody (Fig. 7). In the
supernatants from cells treated with sCD4 or the Arg59-
containing CD4 peptides N22S, S4S, and N22S-F43A, we
observed the gp120 protein, but not in the uninfected cells, or
those treated with the control peptides (I15R and S4R), the
N22S-R59A or the N22S-F43A-R59A peptides. These results
strongly support the hypothesis that Arg59 within the high-
affinity gp120-binding region of CD4 is important for the
conformational changes induced in the gp120 after the CD4-
binding event during the viral entry that leads to the exposure of
the gp41 transmembrane envelope protein.
Discussion
The vast majority of HIV-1 strains depend on the CD4
receptor on human cells for entry and productive infection
because CD4-binding induces conformational changes in the
viral envelope protein gp120 that are essential for the sequential
events in viral entry and infection. A 22-amino acid sequence
(aa 39–60) within the CDR2 domain of the CD4 serves as the
high-affinity gp120-binding region, and based on crystal
structure and mutational analyses several amino acids within
this regions have been proposed to be important for this
interaction, in particular Phe43 and Arg59 (Kwong et al., 1998,
2000). Using this crystal structure information, Claudio Vita's
group designed CD4-mimetics by transferring critical amino
acids within the CDR2-loop into a structurally equivalent
disulfide-stabilized scaffold of the scorpion toxin and showed
the resulting miniprotein of about 25–28 amino acids to possess
potent anti-HIV activity (Drakopoulou et al., 1998). It is
proposed that the phenylalanine at position 23 in this
miniprotein mimicked the Phe43 of CD4 in terms of engaging
the gp120 in tight binding configuration, while arginine at
position 9 in the miniprotein, similar to the Arg59 in CD4, to
form hydrogen bonds with Asp368 in gp120 that are predicted toFig. 6. Arg59-containing CD4 peptides from the high-affinity gp120-binding region
HIV-1IIIB. Chronically HIV-1IIIB-infected H9 cells were incubated with either sCD4 o
and gp41 were determined by staining with anti-gp120 antibody 1121 (A) or the a
intensity of gp120 staining show the background control non-specific signal for med
and I15R (red line). Additional histogram plots show the fluorescence intensity of g
N22S-F43A, N22S-F43A-R59A, and N22S-R59A treatments (red line) in comparis
line). Gp120 binding was greatly reduced when the cells were pretreated with CD4 p
staining in medium-treated control cells (bold line in each panel), or after treatment w
was greatly increased with sCD4, S4S, and N22S treatments. Additional histogram
F43A, N22S-F43A-R59A, and N22S-R59A treatments (red line) in comparison tobe important for CD4-mediated conformational changes in
gp120. On the other hand, Lifson et al. (1988) employed
benzylated peptides spanning amino acids 76–94 in CD4, thus
different from the high-affinity gp120-binding region of CD4,
and showed potent anti-HIV activity. The predicted mechanism
included steric hindrance by the benzylated CD4 peptides for
CD4–gp120 interactions.
In the present investigation, we specifically addressed the
role of Arg59 for the CD4–gp120 interaction in terms of
inducing conformational changes that in turn could influence
entry and productive infection of diverse HIV-1 strains using
synthetic peptides spanning this important CD4 sequence. The
N22S peptide, corresponding to the entire 22-amino acid high-
affinity gp120-binding region of CD4, showed specific binding
to gp120, induced gp120-shedding from chronically HIV-1-
infected cells exposing the viral transmembrane protein gp41,
and loss of infectivity of diverse HIV-1 strains. These results
were confirmed employing tissue culture cell lines as well as
freshly isolated human peripheral blood mononuclear cells for
infection by different laboratory-adopted and primary viral
isolates with distinct host cell co-receptor specificities. How-
ever, a truncated version of the CD4 peptide, N18D, devoid of
Arg59 failed to compete with sCD4 for binding to gp120, and
did not induce conformational changes in gp120 or cause
gp120-shedding in cells infected with multiple strains of HIV-1.
Furthermore, full-length sequences of the N22S peptide with
alanine-substituted for Arg59 were either ineffective or greatly
reduced for all these activities. Finally, a shorter peptide
encompassing the C-terminal 4 amino acids that included
Arg59, was as efficient as the full length CD4 peptide N22S as
well as sCD4 in terms of gp120-shedding and reducing the
infectivity of diverse HIV-1 strains. These results are different to
some extent from those of Martin et al. (2003) who used a CD4induce conformational changes in the envelope protein on cells infected with
r the CD4 peptides (each used at 10 μg/ml) and the cell surface levels of gp120
nti-gp41 antibody 50–69 (B). (A) Histogram plots depicting the fluorescence
ium treatment (bold line), compared to treatment with sCD4, N22S, S4S, S4R,
p120 staining after treatment of the chronically HIV-1IIIB-infected H9 cells with
on to the background control non-specific signal after medium treatment (bold
eptides containing Arg59. (B) Histogram plots of fluorescence intensity of gp41
ith sCD4, N22S, S4S, S4R, or I15R (red line in each panel). The gp41-binding
plots show fluorescence intensity of gp41 staining of cell treated with N22S-
the background control non-specific signal after medium treatment (bold line).
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cally mimic and depend on the strong interaction by Phe43 to
gp120 to exert potent anti-HIV activity. One reason for this
difference is that, unlike these studies where the miniprotein
contained only specific amino acids from the high-affinity
gp120-binding region of CD4, our studies employed peptides
that retained all the amino acids in this CD4 region with specific
alterations for Phe43 and/or Arg59 only (N22S and other variants
of this peptide as shown in Table 1), thereby potentially yielding
differences in the secondary and/or tertiary interactions with
gp120. The potent antiviral activity, including the gp120-
shedding and gp41 exposure by the shorter S4S peptide in our
studies may or may not be similar in the underlying mechanism
to that of the N22S peptide, but we predict that the positioning
of Arg59 in it may specifically mimic the structure required for
inducing the conformational changes in gp120. This is because
the control S4R peptide, where the amino acid sequence is
scrambled changing the position of Arg59, did not show any of
the activities of the S4S peptide (e.g. gp120-shedding and gp41
exposure). Further structure–function studies incorporating this
peptide and its variants will be necessary to better understand
the mechanism of its anti-HIV activity.
Crystallographic studies on CD4–gp120 interaction have
shown that Phe43 within the high-affinity gp120-binding region
of CD4 is inserted into a deep hydrophobic pocket of gp120
suggesting it as a critical event for the docking of the viral
surface envelope protein onto the CD4 receptor on host cells
(Kimpton and Emerman, 1992). The various conformational
changes in the gp120–gp41 envelope complex on the virion
necessary for the post-CD4 viral entry events are predicted to be
initiated and/or brought forth by several of the other amino
acids, including Arg59, within this high-affinity gp120-binding
region of the CD4. Our studies employing peptides correspond-
ing to this CD4 region provide support to this contention and
add to the further understanding of the CD4–gp120 interaction,
by specifically demonstrating the functional significance of
Arg59 for one or more of the events during the host cell entry
and productive infection by diverse HIV-1 strains. Based on the
findings from the present investigation, we propose that Arg59
may play an important role in inducing conformational changes
within the viral envelope protein, specifically in the gp120 that
lead to the exposure of gp41. The CD4 peptide N22S,
encompassing the suggested high-affinity gp120-binding region
in CD4, used in the present investigation should be a valuable
tool for further analysis and understanding of the viral entry
process, specifically conformational changes in the viral
envelope protein complex, gp120–gp41, necessary for the
sequential interaction with other cellular receptors.
Since gp120 on the virion or HIV-infected cells is the most
important ligand for interacting with host–cell receptors like the
CD4 and chemokine receptors, necessary for infection by the
virus or syncytium formation between infected and uninfected
cells, its loss results in the abrogation of infection and
symcytium formation. Therefore, reagents that can induce the
shedding of the gp120 from the virion or infected cells
constitute potential agents for anti-HIV therapeutic strategies.
Results from the present investigation offer one or more suchpotential reagents in the form of synthetic peptides or their
mimetics encompassing the Arg59 from the high-affinity gp120-
binding region of CD4. Future studies including testing the
safety, pharmacokinetics, and bio-availability, should assist in
determining the potential of these peptides for therapeutic and/
or intervention strategies against HIV-1 and AIDS.
Materials and methods
Cell culture and production of viral stock
HeLa CD4+β-gal cells (HeLa β-gal cells) (Kimpton and
Emerman, 1992), the Ghost X4 cells, and the Ghost Hi-5 cells
(Morner et al., 1999) were obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH and maintained in DMEM supplemented with
10% fetal bovine serum (FBS) and the appropriate antibiotics.
The H9/HIVIIIB cells were maintained in RPMI-1640 medium
supplemented with 10% FBS. Primary human peripheral blood
mononuclear cells (PBMCs) were isolated by the Ficoll–
Hypaque density gradient separation method (Pinto et al.,
1995) and cultured in RPMI-1640 supplemented with 10%
FBS and 2 μg/ml phytohemagglutinin (PHA) for 72 h before
using in HIV-1 infection assays. A plasmid encoding the HIV-1
proviral DNA with a defect in the envelope region, pMenv(−),
and two plasmids encoding HIV-1 env sequences representing
clades C and D, 93MW965.26 and 93ZR001.3, respectively,
were obtained through the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH.
Peptides
Linear peptides of 4 to 22 amino acids in length, corre-
sponding to the high-affinity gp120-binding region of CD4
along with alanine substitutions of specific amino acids in
these peptides, were used for various experiments as shown in
Table 1. The peptides were prepared in the institutional
antigen-core facility utilizing FMOC solid phase chemistry on
a PTI Symphony Peptide Synthesizer (Protein Technologies
Inc., Tucson, Arizona). Peptide purity was determined to be
>95% by high-pressure liquid chromatography (HPLC) and
was validated by mass spectrometry. Peptide stock solutions
were prepared in phosphate-buffered saline (PBS, pH 7.0) and
filter-sterilized.
Proteins and antibodies
Recombinant gp120 corresponding to HIV-1IIIB envelope
protein, recombinant human soluble CD4 sCD4, and anti-
gp120 murine monoclonal antibody (1121) were purchased
from ImmunoDiagnostics, Inc. (Woburn, MA). The murine
monoclonal anti-gp120 antibody (902) and the human anti-
gp41 monoclonal antibody (50–69) were obtained through the
AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH. The murine rabbit polyclonal antibody to
human IgG H and L (FITC-labeled) and goat polyclonal
antibody to mouse IgG (FITC-labeled) were purchased from
77D. Fontenot et al. / Virology 363 (2007) 69–78Abcam (Cambridge, MA). The Super Signal West Femto
Maximum Sensitivity Substrate along with the HRP-conju-
gated goat anti-rabbit antibody and HRP-conjugated goat anti-
mouse antibody were purchased from Pierce Biotechnology,
Inc. (Rockford, IL). The Human CXCR4 mAb (Clone 44717)
and the recombinant human SDF-1β were purchased from
R&D Systems, Inc. (Minneapolis, MN).
Fluorescent assay for HIV-1 infection
GHOST cells were plated in 12 well plates at 1.2×105 cells
per well in complete DMEM the day before the infection. After
overnight incubation, medium was removed from each well and
1 ml of fresh DMEM/10% FBS was added in each well before
infection. A 10 μg/ml concentration of the sCD4 or control
peptides was added to a fixed amount of HIV and incubated at
37 °C for 30 min. The peptide/virus mixture was added to cells
and incubated at 37 °C in a 5% CO2 incubator. Twenty-four
hours after infection, the inoculum was removed and 1 ml of
DMEM was added for an additional 24 h. After 48 h of total
time, the medium was removed and the cells were collected and
fixed with a 2% formaldehyde, 0.2% glutaraldehyde, and
phosphate-buffered saline (PBS) solution for 10 min. Cells were
then washed twice with PBS, resuspended in 0.5 ml PBS and
analyzed for GFP production by flow cytometry.
Reverse transcriptase activity
Culture supernatant was precipitated with 30% polyethy-
lene glycol of 50% volume of the original culture supernatant.
RT activity was measured according to a modification of
Nehete et al. (1993).
ELISA for determining the binding of the CD4 peptides to
HIV-1 gp120
Recombinant gp120 corresponding to HIV-1IIIB (Immuno-
Diagnostics, Inc., Woburn, MA) at a concentration of 1 μg/ml in
0.1 M NaHCO3 was used to coat the wells of a 96-well plate.
The plate was incubated overnight at 37 °C in a 5% CO2
incubator. After the incubation, the coating solution was
discarded and 150 μl of non-fat dry milk blocking solution
(5 g NFDM in 100 ml of TBS) was added to each well. The
plate was covered in saran wrap and placed in the 37 °C
incubator for 1–1.5 h. At the end of the incubation, the blocking
solution was discarded and either sCD4 or the various CD4
peptides in T-wash solution (2 g NFDM, 50 ml 1× TBS, 40 μl
Tween 20), at a concentration of 1 μg, were added to each
coated well. The plate was covered in saran wrap and incubated
at 37 °C for 1–1.5 h. The wells were then washed 3× with TBS
containing 0.05% Tween 20. After the washes, the HRP
conjugated CD4 antibody (Goat anti-rabbit IgG (h+ l); Zymed,
San Francisco, CA) was added at a 1:28,000 dilution and the
plate was incubated for 1 h. After the incubation, the plate was
washed three times with TBS containing 0.05% Tween 20 and
100 μl of the TMB substrate (Bethyl Laboratories, Montgom-
ery, TX) was added for 15 min at room temperature. Thereaction was stopped by the addition of 100 μl of 2 M H2SO4
and the wells were read in an ELISA reader at 450 nm.
Antibody staining and analysis of cells
H9 cells expressing HIV envelope glycoprotein, were
suspended in RPMI/10% FBS at a concentration of 5×105
cells/ml. CD4 peptides, control peptide, and sCD4 were added
to 100ul of the cell suspension at 10ug/ml for 4 hr at 37 °C.
Cells were then pelleted and washed using FACS washing
buffer and resuspended in 100 μl FACS wash. Either murine
monoclonal antibody anti-gp120 (1121) or human monoclonal
antibody anti-gp41 (50–69) was added to the cell suspension for
30 min on ice. Cells were then washed and resuspended in 100
μl FACS wash. FITC-labeled secondary antibody was then
added to the cell suspension for 30 min on ice, then cells were
washed, fixed with a 1% solution of paraformaldehyde, and
analyzed by flow cytometry.
Analysis of gp120 release
Chronically infected H9/HIVIIIB cells were collected at
1×107 in 250 μl of serum free RPMI. CD4 peptides, control
peptide, and sCD4 were added to cells at 10 μg/ml for 1 h at
37 °C. Following the incubation, the cells were pelleted and the
cell free supernatant was collected and treated with Triton-X
100 to inactivate the virus. The supernatant was roto-vaped at
45 °C for 3 h to concentrate the sample amount to 30 μl, which
was then mixed with 4× loading buffer and resolved on an 8%
SDS polyacrylamide gel followed by transfer to nitrocellulose
filters for Western blot analysis using murine monoclonal anti-
gp120 antibody (902) as the primary antibody, followed by
horseradish peroxidase-labeled goat anti-mouse IgG H&L and
the femto fluorometric system.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.virol.2006.12.003.
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